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Missing heritability 
What is missed by genomewide 
association scans 
• SNPs with smaller effects 
– Strict p-values – larger samples/meta-analysis 
• Rare variants 
– Included on newer chips – but low power 
• Copy number variants 
– Mostly rare 
• Parent of origin effects 
• Gene-gene interaction 
– Gene-gene or SNP-SNP 
• Heritability probably over-estimated originally 
 
 
Evidence for SNPs with smaller effects 
The International Schizophrenia Consortium Nature 000, 1-5 (2009) doi:10.1038/nature08185 
Replication of the ISC-derived polygenic component in 
independent schizophrenia and bipolar disorder samples. 
• Take all SNPs with P<PT in the 
ISC sample 
• Calculate a score for each subject 
based on these SNPs 
• #risk alleles carried 
• Associate this score with the 
phenotype 
• Replicates “en-masse” SNPs in 
independent schizophrenia data 
• Shows common genetic component 
between schiz and bipolar disorder 
Copy number variation 
• Very few SNP associations in GWAS 
• ASD cases carry more rare CNVs 
than do controls 
• CNVs must cause ASD, but hard to 
identify individual variants 
Much heritability is tagged in GWAS 
The SNPs are there, but are not statistically significant 
GWAS hits are enriched in functional regions 
Pathway analysis 
• Aims to find association of a group of 
functionally related genes 
– Individual SNPs may not be significant 
– Can enhance the results of GWAS by finding 
associated pathways 
• Various databases of biological pathways 
– eg GO, KEGG, BioCarta, Panther, Reactome 
• Test whether more SNPs in the pathway are 
significant at some threshold (eg P<0.01) 
than SNPs outside the pathway 
• Complex methods allow for network structure 
Example – Alzheimer’s Disease 
More enriched pathways than expected 
SNP list 
criterion 
#genes 
enrichment 
p<0.05 
enrichment 
p<0.01 
enrichment 
p<0.001 
#cat p #cat p #cat p 
p<1e-4 72 115 0.009 50 0.006 16 0.008 
p<1e-3* 589 254 0.005 127 <0.001 57 <0.001 
p<0.005 2212 291 0.006 76 0.006 18 <0.001 
p<0.01 3703 282 0.023 64 0.031 8 0.110 
p<0.05 10709 228 0.078 44 0.096 4 0.295 
Top GO categories 
category 
total
in GWAS expected
GO:0008203 83 11 2.54 0.00E+00 0.06 cholesterol metabolic process                                                                                                                                                                           
GO:0016125 92 12 2.85 0.00E+00 0.06 sterol metabolic process                                                                                                                                                                                
GO:0032488 4 3 0.25 2.00E-05 0.10 Cdc42 protein signal transduction                                                                                                                                                                       
GO:0006958 29 6 0.72 2.00E-05 0.10 complement activation, classical pathway                                                                                                                                                                
GO:0002455 29 6 0.72 2.00E-05 0.10 humoral immune response mediated by circulating immunoglobulin                                                                                                                                          
GO:0008202 175 16 5.65 4.00E-05 0.13 steroid metabolic process                                                                                                                                                                               
GO:0033700 8 4 0.45 6.00E-05 0.16 phospholipid efflux                                                                                                                                                                                     
GO:0002253 60 8 1.43 6.00E-05 0.16 activation of immune response                                                                                                                                                                           
GO:0045087 118 11 2.74 1.00E-04 0.25 innate immune response                                                                                                                                                                                  
GO:0006956 37 6 0.81 1.60E-04 0.40 complement activation                                                                                                                                                                                   
GO:0002541 39 6 0.85 1.80E-04 0.44 activation of plasma proteins during acute inflammatory response                                                                                                                                        
GO:0050746 6 3 0.18 2.20E-04 0.52 regulation of lipoprotein metabolic process                                                                                                                                                             
GO:0030001 423 36 20 3.00E-04 0.71 metal ion transport                                                                                                                                                                                     
GO:0006812 499 38 21.69 3.60E-04 0.84 cation transport                                                                                                                                                                                        
GO:0015672 298 25 12.59 5.40E-04 1.30 monovalent inorganic cation transport                                                                                                                                                                   
GO:0048583 237 16 6.45 5.80E-04 1.37 regulation of response to stimulus                                                                                                                                                                      
GO:0034447 3 2 0.06 6.40E-04 1.50 very-low-density lipoprotein particle clearance                                                                                                                                                         
GO:0022411 50 6 1.24 6.80E-04 1.59 cellular component disassembly                                                                                                                                                                          
GO:0016064 47 6 1.12 6.80E-04 1.59 immunoglobulin mediated immune response                                                                                                                                                                 
GO:0019724 49 6 1.17 8.80E-04 2.05 B cell mediated immunity                                                                                                                                                                                
GO:0002526 73 7 1.59 9.20E-04 2.14 acute inflammatory response                                                                                                                                                                             
Process
Genes 
GO process p-value
expected 
hits/study
Risk prediction 
• A great hope of genetics is that we can accurately predict an 
individual’s risk of disease 
– Early intervention 
– Enrolment in screening programmes, eg mammography 
– Selection of individuals for research trials 
• In Mendelian monogenic disease, such prediction is already in 
clinical use 
– Disease mutations have very high penetrance 
– Genetic counselling, IVF screening 
• Not so clear-cut in complex disease: genes have small effects 
 
 
 
Issues in genetic risk prediction 
• Sensitivity 
– How many cases of disease are correctly predicted by genetics? 
• Specificity 
– How many non-cases of disease are falsely predicted as cases? 
• Area under ROC curve (AUC) 
– Summarises sensitivity and specificity over the range of risk scores 
– 0.99 for population screening, 0.75 for screening “at-risk” subjects 
– 0.5 is no better than random prediction 
• Positive predictive value 
– If disease is predicted, what’s the chance of actually developing  it? 
– Particularly challenging in rare diseases 
• Does genetics improve on established risk prediction models? 
 
Distribution of risk 
• Assuming that risk is due to many genes of small effect, the 
log-risk is normally distributed in the population 
• The variance of the risk depends on the heritability 
Distribution of risk for multiple sclerosis, s=10 
Sawcer et al, Ann Neurol 2010 
Risk in the cases 
• Looking at those who did develop disease, we can look at 
what risk they had carried 
• This is also normally distributed, but with a higher mean 
Pharoah et al, Nat Genet 2002 
Limits on predictive power of genetics 
• The distributions of risk in the population and in the cases 
imply a limit on the ROC curve 
• The heritability places a limit on how good prediction can ever 
be, even if we knew all the genes that cause disease 
– For many common diseases, genetics can never give a great AUC 
Clayton, PLoS Genetics 2009 
Type-1 diabetes 
Schizophrenia 
Breast cancer 
Large samples needed to derive accurate predictors 
• If disease is explained by hundreds or thousands of SNPs, very 
large samples are needed to minimise the sampling error in 
the risk score 
• Possibly 100,000’s of cases and controls 
100k SNPs explaining half the heritability 
Varying proportions of null SNPs 
Family history  
• Family history of a trait can predict almost all well as the 
individual genetics 
 
Aulchenko et al, Predicting human height by 
Victorian and genomic methods, Eur J Hum 
Genet 2009 
54 known genes 
Mid-parental height 
Genes 
explaining 
100% 
heritability 
Utility of genetic risk prediction 
• Genetics offers real benefits over family history and lifestyle 
risk prediction at the population level only when: 
– Heritability is fairly high 
– Genes explain a high proportion of the heritability 
• Genetic prediction more useful in specific contexts 
– Identifying individuals for more intensive, non-invasive screening 
– Predicting molecular biomarkers rather than disease endpoints 
– Predicting time-to-disease, allowing early intervention 
– Predicting adverse drug reactions 
– Selecting at-risk individuals for trials 
Commercial prediction kits – caveat emptor! 

Mendelian Randomisation 
• An application of genetics to reduce problems in traditional 
observational epidemiology 
• “Association does not equal causation” 
 
1. Confounding 
 
 
2. Reverse causality 
Alcohol 
consumption Heart disease 
Socio-economic 
status 
? 
Heart disease Obesity 
? 
? 
Observation vs randomisation 
• In randomised clinical trials, confounding and reverse 
causation are reduced or even eliminated 
– “Treatment” and “Placebo” groups differ only in the treatment 
received, and by no other characteristics 
– Events that follow treatment (in time) are more likely to be caused by 
the treatment 
• Some experiments cannot be performed with randomisation 
– Effects of smoking or alcohol 
– Socio-economic effects 
• Observational studies are the only ethical option 
 
Mendelian Randomisation principle 
• Genes are randomly allocated, independent of confounders 
• Genes cause phenotypes, but phenotypes do not cause genes 
• Therefore, a gene that causes the exposure of interest can be 
a proxy for that exposure, without confounding or reverse 
causation 
 
Gene that 
influences 
alcohol 
consumption 
Heart disease 
Socio-economic 
status 
? 
X 
X 
Mendelian randomisation analysis  
“Instrumental variable” technique  
Intermediate  
Phenotype 
Disease Genotype 
(IP difference/ 5) 
Confounders 
U 
Y X Z 
Assumptions of IV technique for Mendelian randomisation:  
1. The Instrumental variable (IV) Z is associated with exposure of interest X  
2. Z is independent of the confounding factors  U (that confound X-Y association) 
3. Z is independent of outcome Y given X and the confounding factors U  3.   Genotype is r lated to the outcom  only via its associatio  with the modifiable         
    exposure 
bXY = bZY  bZX 
^ ^ ^ 
bXY bXY 
• For more on Mendelian Randomisation, and other aspects of 
causal inference: 
 
Causal Inference in Epidemiology: recent methodological 
developments 
November 2013 
Duration: One week 
http://www.lshtm.ac.uk/study/cpd/causal_inference.html 
 
Epigenetics 
• Heritable information that is not encoded in the DNA 
sequence 
• NB “heritable” often refers to regeneration of cells within one 
organism 
• For genetic epidemiology, transgenerational epigenetics may 
be more relevant 
Epigenetic modifications 
• Most common: DNA methylation 
– Chemical alteration to DNA molecule, usually a CpG dinucleotide 
– Has a number of effects on gene expression and regulation 
– Can be induced by environment and inherited transgenerationally 
– Allele-specific methylation: SNP associated with methylation status 
• Also: histone modification 
– Changes the 3D “wrapping” of DNA inside the nucleus 
 
• These mechanisms provide a way to explain the molecular 
effects of environmental exposures, and to map the path from 
genotype to phenotype 
– Rakyan et al, Nat Rev Genet 2011; Daxinger & Whitelaw, Nat Rev Genet 2012 
Prospects 
• Most current activity is still in finding genes that cause disease 
– So far, few traits have more than 25% heritability explained 
– Account for the “missing heritability” 
• Even where associations have been validated, the causal 
variants have not been identified 
– Only have SNPs in linkage disequilibrium with causal variant 
– Needs genotyping in multiple populations, sequencing, and functional 
biology 
• However, as we have seen, the identification of disease genes 
is leading to increased interest in applications to public health 
